Ethnic variability in methotrexate pharmacogenetics among rheumatoid arthritis populations: a narrative review
DOI:
https://doi.org/10.22146/ijpther.29118Keywords:
Ethnic variability, Polymorphism, Methotrexate, Pharmacogenetics, Rheumatoid arthritisAbstract
Methotrexate is the recommended first-line conventional disease-modifying antirheumatic drug for rheumatoid arthritis; interindividual variability in treatment response and toxicity remains a major clinical challenge. Pharmacogenomics provides a biological basis for this variability, yet reported associations between genetic polymorphisms and methotrexate outcomes are often inconsistent across populations. This narrative review synthesizes current evidence on ethnic variability in methotrexate pharmacogenetic associations among patients with rheumatoid arthritis. A structured literature search was conducted in PubMed/MEDLINE, Scopus, and Google Scholar up to January 2026, including human studies evaluating genetic polymorphisms in methotrexate-related pathways and reporting outcomes related to treatment effectiveness or toxicity. The available evidence is dominated by observational studies in populations of European and East Asian ancestry, with limited data from Southeast Asian cohorts. Polymorphisms in genes involved in methotrexate transport, intracellular activation, folate-dependent metabolism, and drug efflux demonstrate substantial interethnic differences in allele frequencies and reported clinical associations. Variants in folate metabolism genes are more consistently associated with methotrexate-related toxicity than with treatment effectiveness, whereas transporter and downstream pathway variants show population-dependent and heterogeneous associations with effectiveness. These inconsistencies are further influenced by methodological heterogeneity, including differences in outcome definitions, methotrexate dosing, folate supplementation, sample size, and adjustment for concomitant therapies. Overall, ethnic variability appears to be a key determinant of methotrexate pharmacogenetic associations in rheumatoid arthritis. Population-specific studies using standardized disease activity outcomes are required, particularly in underrepresented Southeast Asian populations especially Indonesia, to support equitable implementation of precision medicine strategies.
References
Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. Pharmacol Rev 2023; 75(4):789–814.
https://doi.org/10.1124/pharmrev.122.000810
Al-Sofi RF, Bergmann MS, Nielsen CH, Andersen V, Skov L, Loft N. The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Int J Mol Sci 2024; 25(11):1–21.
https://doi.org/10.3390/ijms25115793
Conti V, Corbi G, Costantino M, De Bellis E, Manzo V, Sellitto C, et al. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics. Biomolecules 2020 14; 10(12):1672.
https://doi.org/10.3390/biom10121672
Dipiro JT. Pharmacotheraphy: A Pathophysiologic Approach. Penambahan Natrium Benzoat Dan Kalium Sorbat (Antiinversi) Dan Kecepatan Pengadukan Sebagai Upaya Penghambatan Reaksi Inversi Pada Nira Tebu. 2023.
Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2021; 73(7):924–39.
https://doi.org/10.1002/acr.24596
Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 2023; 5(10):e594–610.
https://doi.org/10.1016/S2665-9913(23)00211-4
van Riel PLCM, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34(5 Suppl 101):S40–4.
Moya P, Salazar J, Arranz MJ, Díaz-Torné C, Del Río E, Casademont J, et al. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics 2016; 17(1):25–9.
https://doi.org/10.2217/pgs.15.150
Wright NJ, Fedor JG, Zhang H, Jeong P, Suo Y, Yoo J, et al. Methotrexate recognition by the human reduced folate carrier SLC19A1. Nature 2022; 609(7929):1056–62.
https://doi.org/10.1038/s41586-022-05168-0
Karamperis K, Katz S, Melograna F, Ganau FP, Van Steen K, Patrinos GP, et al. Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity. iScience 2024; 27(10):110916.
https://doi.org/10.1016/j.isci.2024.110916
Masoumi M, Solaymani M, Abbasifard M, Houshmandfar S, Iravani P, Saeedi-Boroujeni A, et al. The genetic puzzle of rheumatoid arthritis: Causes, progression, and treatment. Biochem Biophys Rep 2025; 43:102148.
https://doi.org/10.1016/j.bbrep.2025.102148
Qiu Q, Huang J, Shu X, Fan H, Zhou Y, Xiao C. Polymorphisms and pharmacogenomics for the clinical efficacy of methotrexate in patients with rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep 2017; 7:44015.
https://doi.org/10.1038/SREP44015
Ranasinghe P, Sirisena N, Vishnukanthan T, Ariadurai JN, Thilakarathne S, Priyadarshani CDN, et al. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka. BMC Med Genomics 2024; 17(1):143.
https://doi.org/10.1186/s12920-024-01919-2
Premkumar B. Genetic polymorphisms influencing efficacy and safety of methotrexate in rheumatoid arthritis. Asian J Pharm Clin Res 2018; 11(8):395–401.
https://doi.org/10.22159/ajpcr.2018.v11i8.24563
Sha HX, Veerapen K, Chow SK, Gun SC, Lau IS, Lim RLH, et al. Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia. Sci Rep 2022; 12(1):11844.
https://doi.org/10.1038/s41598-022-15991-0
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020; 16(3):145–54.
https://doi.org/10.1038/s41584-020-0373-9
Zhao X, Wu P, Yang Z, Miao RR. Relationship between the efficacy and adverse effects of methotrexate and gene polymorphism. Egypt J Med Hum Genet 2024; 25(89):1-11.
https://doi.org/10.1186/s43042-024-00562-x
Babiker-Mohamed MH, Bhandari S, Ranganathan P. Pharmacogenetics of therapies in rheumatoid arthritis: An update. Best Pract Res Clin Rheumatol 2024; 38(4):101974.
https://doi.org/10.1016/j.berh.2024.101974
Jouybari MT, Mojtahedi F, Babaahmadi M, Faeed M, Eslaminejad MB, Taghiyar L. Advancements in extracellular vesicle targeted therapies for rheumatoid arthritis: insights into cellular origins, current perspectives, and emerging challenges. Stem Cell Res Ther 2024; 15(1):276.
https://doi.org/10.1186/s13287-024-03887-x
Huang J, Fan H, Qiu Q, Liu K, Lv S, Li J, et al. Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis. Ther Adv Chronic Dis 2020; 11:2040622320916026.
doi:10.1177/2040622320916026
Abdallah HY, Ibrahim ME, Abd El-Fadeal NM, Ali DA, Elsehrawy GG, Badr RE, et al. Pharmacogenomics of methotrexate pathway in rheumatoid arthritis patients: approach toward personalized medicine. Diagnostics 2022; 12(7):1560.
https://doi.org/10.3390/diagnostics12071560
Ghodke‐Puranik Y, Puranik AS, Shintre P, Joshi K, Patwardhan B, Lamba JK, et al. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics 2015; 16(18):2019-34.
https://doi.org/10.2217/PGS.15.145
Nomair AM, Abdelati A, Dwedar FI, Elnemr R, Kamel YN, Nomeir HM. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clin Rheumatol 2024; 43(3):971–83.
https://doi.org/10.1007/s10067-024-06892-w
Jenko B, Lusa L, Tomsic M, Praprotnik S, Dolzan V. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J 2017; 17(5):412–8.
https://doi.org/10.1038/tpj.2016.36
Grabar PB, Leandro-García LJ, Inglada-Pérez L, Logar D, Rodríguez-Antona C, Dolžan V. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. Pharmacogenomics 2012; 13(14):1583–94.
https://doi.org/10.2217/pgs.12.150
James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008; 35(4):562–71.
Cen H, Wen QW, Zhang HQ, Yu H, Zeng Z, Jin T, et al. Associations between genetic polymorphisms within transporter genes and clinical response to methotrexate in chinese rheumatoid arthritis patients: a pilot study. Pharmacogenomics Pers Med 2022; 15:327–39.
https://doi.org/10.2147/PGPM.S350417
Hakamata J, Kaneko Y, Shimizu M, Yamaoka K, Maruyama J, Takeuchi T, et al. Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis: A hospital-based cohort study. Biol Pharm Bull 2018; 41(9):1414–22.
https://doi.org/10.1248/bpb.b18-00247
Wang S, Zuo S, Liu Z, Ji X, Yao Z, Wang X. Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis. J Int Med Res 2019; 48(2): 300060519879588.
https://doi.org/10.1177/0300060519879588
López-Rodríguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A, et al. Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep 2018; 8(1):7342.
https://doi.org/10.1038/s41598-018-25634-y
Yamamoto T, Shikano K, Nanki T, Kawai S. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. Sci Rep 2016; 6(1):35615.
https://doi.org/10.1038/srep35615
Muralidharan N, Sundaram R, Kodidela S, Chengappa KG, Mariaselvam CM, Misra DP, et al. Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients. Pharmacogenomics J 2020; 20(2):342–9.
https://doi.org/10.1038/s41397-019-0097-x
Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 2013; 13(3):227–34.
https://doi.org/10.1038/tpj.2012.7
Zhang Q, Fu P, Cao Z, Huang H, Wen Q, Wang K, et al. MTHFR and MTRR genetic polymorphism of methotrexate therapy outcomes in early rheumatoid arthritis. Pharmacogenomics Pers Med 2023; 16:407–23.
https://doi.org/10.2147/PGPM.S404949
D’Cruz LG, McEleney KG, Tan KBC, Shukla P, Gardiner PV, Connolly P, et al. Clinical and laboratory associations with methotrexate metabolism gene polymorphisms in rheumatoid arthritis. J Pers Med 2020; 10(4):149.
https://doi.org/10.3390/jpm10040149
Chaabane S, Marzouk S, Akrout R, Ben Hamad M, Achour Y, Rebai A, et al. Genetic determinants of methotrexate toxicity in tunisian patients with rheumatoid arthritis: a study of polymorphisms involved in the MTX metabolic pathway. Eur J Drug Metab Pharmacokinet 2016; 41(4):385–93.
https://doi.org/10.1007/s13318-015-0288-z
Kurzawski M, Malinowski D, Szarmach N, Nowak A, Goryniak A, Pawlik A, et al. ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients. Pharmacogenomics 2016; 17(18):1971–8.
https://doi.org/10.2217/pgs-2016-0125
Lv S, Fan H, Li J, Yang H, Huang J, Shu X, et al. Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR are related to the outcome of methotrexate therapy for rheumatoid arthritis in a chinese population. Front Pharmacol 2018; 9:1390.
https://doi.org/10.3389/fphar.2018.01390
Melikoglu MA, Balkan E. Can we predict unresponsiveness to methotrexate in rheumatoid arthritis? A pharmacogenetic study. Inflammopharmacology 2022; 30(1):193–7.
https://doi.org/10.1007/s10787-021-00921-9
Escudero-Contreras A, López-Medina C, Collantes-Estévez E, Ortega-Castro R, Calvo-Gutiérrez J, Mena-Vázquez N, et al. Genetic polymorphisms of GGH and ABCC2 are associated with methotrexate intolerance in patients with rheumatoid arthritis. J Clin Med 2021; 10(18):4070.
https://doi.org/10.3390/jcm10184070
Jerzy ͆wierkot, Ryszard ͆lęzak, Karpiński P, Pawłowska J, Noga L, Szechiński J, et al. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol Arch Med Wewn 2015; 125(3):152–61.
https://doi.org/10.20452/pamw.2707
Ceballos FC, Chamizo-Carmona E, Mata-Martín C, Carrasco-Cubero C, Aznar-Sánchez JJ, Veroz-González R, et al. Pharmacogenetic sex-specific effects of methotrexate response in patients with rheumatoid arthritis. Pharmaceutics 2023; 15(6):1661.
https://doi.org/10.3390/pharmaceutics15061661
Gallardo-Moya SG, Gonzalez-Lopez L, Contreras-Haro B, Mireles-Ramirez MA, Villagomez-Vega A, Morán-Moguel MC, et al. Genetic variants of the ATIC gene and therapeutic response to methotrexate in patients with rheumatoid arthritis. Int J Mol Sci 2025; 26(9):4013.
https://doi.org/10.3390/ijms26094013
Cwiklinska M, Czogala M, Kwiecinska K, Madetko-Talowska A, Szafarz M, Pawinska K, et al. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and tandem TS repeats influence pharmacokinetics, acute liver toxicity, and vomiting in children with acute lymphoblastic leukemia treated with high doses of methotrexate. Front Pediatr 2020; 8:1–12.
https://doi.org/10.3389/fped.2020.00307
Chen L, Wu B, Mo L, Chen H, Zhao Y, Tan T, et al. Associations between biological ageing and the risk of, genetic susceptibility to, and life expectancy associated with rheumatoid arthritis: a secondary analysis of two observational studies. Lancet Healthy Longev 2024; 5(1):e45–55.
https://doi.org/10.1016/S2666-7568(23)00220-9
Jenko B, Tomšič M, Jekić B, Milić V, Dolžan V, Praprotnik S. Clinical pharmacogenetic models of treatment response to methotrexate monotherapy in Slovenian and Serbian rheumatoid arthritis patients: Differences in patient’s management may preclude generalization of the models. Front Pharmacol 2018; 9:1–8.
https://doi.org/10.3389/fphar.2018.00020
Londono J, Saldarriaga EL, Rueda J, Giraldo‑Bustos R, Angarita JI, Restrepo L, et al. Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis. Biomed Rep 2020; 13(4):34.
https://doi.org/10.3892/br.2020.1341
Lima Á, Bernardes M, Azevedo R, Seabra V, Medeiros R. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics 2016; 17(15):1649-74.
https://doi.org/10.2217/PGS-2016-0067
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79(6):S685–99.
